We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Read MoreHide Full Article
Key Takeaways
J&J expects 2026 revenues to rise over 5%, above the 4.6% consensus estimate.
Innovative Medicine growth is likely to accelerate, driven by Darzalex, Tremfya and new oncology launches.
MedTech momentum to build on new products like Shockwave C2 Aero and Tecnis intraocular lens.
On its third-quarter earnings conference call on Oct. 14, Johnson & Johnson (JNJ - Free Report) discussed its preliminary outlook for 2026. J&J said that the consensus estimates for 2026, for both the top and the bottom lines, are too low.
In 2026, J&J expects top-line growth of more than 5% while the consensus estimate is around 4.6%. EPS growth is expected to be similar to revenue growth. J&J expects adjusted EPS to be around 5 cents more than the consensus of $11.39 per share. The Zacks Consensus Estimate for 2026 revenue growth is 4.8% while the same for EPS is pegged at $11.46 per share.
J&J expects growth in both the Innovative Medicine and MedTech segments to accelerate in 2026.
In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite the loss of exclusivity (“LOE”) of blockbuster drug, Stelara. Several biosimilar versions of J&J’s multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025.
According to patent settlements and license agreements, Amgen (AMGN - Free Report) , Teva Pharmaceutical Industries (TEVA - Free Report) , Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara’s LOE negatively impacted the Innovative Medicines segment growth by 1070 basis points in the second quarter.
In the first nine months of 2025, Innovative Medicine Unit’s sales rose 4.5% on an operational basis to $44.64 billion.
Innovative Medicine Unit’s growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey. Recently launched products, including Tremfya in inflammatory bowel disease (IBD), Rybrevant plus Lazcluze in non-small cell lung cancer and the newly approved drug, Inlexzo in bladder cancer, are also expected to contribute.
In the MedTech segment, J&J expects better growth than 2025 levels, driven by increased adoption of newly launched products across all MedTech platforms and increased focus on higher-growth markets. J&J expects to launch products like Shockwave C2 Aero catheter and Tecnis intraocular lens in the United States, as well as make a regulatory submission for the OTTAVA robotic surgical system in 2026. These new products may also contribute to growth in 2026.
In the first nine months of 2025, MedTech’s sales rose 5.3% on an operational basis to $25.0 billion.
J&J’s 2026 guidance signals more than optimism—it highlights a deliberate pivot toward innovation-led growth in both segments. With a strong pipeline and robust product launches, J&J seems prepared to deliver beyond the Street’s current expectations.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 34.0% in the year-to-date period compared with a 5.1% increase in the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 17.08 forward earnings, higher than 15.52 for the industry. The stock is also trading above its five-year mean of 15.64.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.86 per share, while that for 2026 has risen from $11.38 to $11.46 over the past seven days.
Image: Bigstock
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Key Takeaways
On its third-quarter earnings conference call on Oct. 14, Johnson & Johnson (JNJ - Free Report) discussed its preliminary outlook for 2026. J&J said that the consensus estimates for 2026, for both the top and the bottom lines, are too low.
In 2026, J&J expects top-line growth of more than 5% while the consensus estimate is around 4.6%. EPS growth is expected to be similar to revenue growth. J&J expects adjusted EPS to be around 5 cents more than the consensus of $11.39 per share. The Zacks Consensus Estimate for 2026 revenue growth is 4.8% while the same for EPS is pegged at $11.46 per share.
J&J expects growth in both the Innovative Medicine and MedTech segments to accelerate in 2026.
In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite the loss of exclusivity (“LOE”) of blockbuster drug, Stelara. Several biosimilar versions of J&J’s multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025.
According to patent settlements and license agreements, Amgen (AMGN - Free Report) , Teva Pharmaceutical Industries (TEVA - Free Report) , Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara’s LOE negatively impacted the Innovative Medicines segment growth by 1070 basis points in the second quarter.
In the first nine months of 2025, Innovative Medicine Unit’s sales rose 4.5% on an operational basis to $44.64 billion.
Innovative Medicine Unit’s growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey. Recently launched products, including Tremfya in inflammatory bowel disease (IBD), Rybrevant plus Lazcluze in non-small cell lung cancer and the newly approved drug, Inlexzo in bladder cancer, are also expected to contribute.
In the MedTech segment, J&J expects better growth than 2025 levels, driven by increased adoption of newly launched products across all MedTech platforms and increased focus on higher-growth markets. J&J expects to launch products like Shockwave C2 Aero catheter and Tecnis intraocular lens in the United States, as well as make a regulatory submission for the OTTAVA robotic surgical system in 2026. These new products may also contribute to growth in 2026.
In the first nine months of 2025, MedTech’s sales rose 5.3% on an operational basis to $25.0 billion.
J&J’s 2026 guidance signals more than optimism—it highlights a deliberate pivot toward innovation-led growth in both segments. With a strong pipeline and robust product launches, J&J seems prepared to deliver beyond the Street’s current expectations.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 34.0% in the year-to-date period compared with a 5.1% increase in the industry.
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 17.08 forward earnings, higher than 15.52 for the industry. The stock is also trading above its five-year mean of 15.64.
The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.86 per share, while that for 2026 has risen from $11.38 to $11.46 over the past seven days.
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.